After starting to gut most of its staff this week, Aveo Oncology ($AVEO) has started down a longer path to potential approval of its top drug candidate tivozanib, which the company no longer plans to develop for kidney cancer. In an analysis for TheStreet, biotech investor Pieter Droppert writes that the future of the VEGF-targeted drug lies in triple-negative breast cancer (TNBC). Patients with TNBC have few treatment options, and Aveo aims to show in an ongoing Phase II study that tivo can benefit women with the disease. Yet investors must wait until late 2014 or early 2015 for results of the midstage study of the drug in patients with this tough-to-treat form of breast cancer. Droppert, an investor in Aveo, makes an adequate bull case for the stock, which has plunged more than 69% so far this year. Item